Investments in R&D, technology can make Indian pharma industry atma nirbhar in the next 2-3 years: Gowda Read more
Serum Institute to produce up to additional 100 mn COVID-19 vaccine doses for India and LMIC in 2021 Read more
Pfizer get USFDA nod for XELJANZ (tofacitinib) to treat active polyarticular course juvenile idiopathic arthritis Read more